Foresite Capital Opportunity Management V 13F annual report

Foresite Capital Opportunity Management V is an investment fund managing more than $39.7 million ran by James Tananbaum. There are currently 9 companies in Mr. Tananbaum’s portfolio. The largest investments include Pardes Biosciences Inc and Theseus Pharmaceuticals, Inc., together worth $21.4 million.

$39.7 million Assets Under Management (AUM)

As of 5th August 2022, Foresite Capital Opportunity Management V’s top holding is 5,227,307 shares of Pardes Biosciences Inc currently worth over $16 million and making up 40.4% of the portfolio value. In addition, the fund holds 959,275 shares of Theseus Pharmaceuticals, Inc. worth $5.31 million. The third-largest holding is Compass Therapeutics, Inc. worth $4.12 million and the next is Gemini Therapeutics, Inc. worth $4.12 million, with 2,435,125 shares owned.

Currently, Foresite Capital Opportunity Management V's portfolio is worth at least $39.7 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Foresite Capital Opportunity Management V

The Foresite Capital Opportunity Management V office and employees reside in Larkspur, California. According to the last 13-F report filed with the SEC, James Tananbaum serves as the Managing Member at Foresite Capital Opportunity Management V.

Recent trades

In the most recent 13F filing, Foresite Capital Opportunity Management V revealed that it had opened a new position in Hims & Hers Health and bought 306,431 shares worth $1.39 million. This means they effectively own approximately 0.1% of the company. Hims & Hers Health makes up 100.0% of the fund's Consumer Staples sector allocation and has decreased its share price by approximately 0.1% in the past year.

The investment fund also strengthened its position in Theseus Pharmaceuticals, Inc. by buying 490,455 additional shares. This makes their stake in Theseus Pharmaceuticals, Inc. total 959,275 shares worth $5.31 million.

On the other hand, there are companies that Foresite Capital Opportunity Management V is getting rid of from its portfolio. Foresite Capital Opportunity Management V closed its position in Cue Health Inc. on 12th August 2022. It sold the previously owned 641,483 shares for $4.14 million. James Tananbaum also disclosed a decreased stake in Quantum-si Incorporated by 0.6%. This leaves the value of the investment at $1.47 million and 633,626 shares.

One of the smallest hedge funds

The two most similar investment funds to Foresite Capital Opportunity Management V are Power Corp Of Canada and Upfront Ventures Management. They manage $39.7 million and $39.7 million respectively.

James Tananbaum investment strategy

Foresite Capital Opportunity Management V’s portfolio is diversified across 3 sectors. Currently, their heaviest sector is Health Care — making up 12.0% of the total portfolio value. The fund focuses on investments in the United States as 33.3% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $1.13 billion.

The complete list of Foresite Capital Opportunity Management V trades based on 13F SEC filings

These positions were updated on August 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Pardes Biosciences Inc	No change 5,227,307	$16,048,000	40.44%
Theseus Pharmaceuticals, Inc.	104.61% 959,275	$5,305,000	13.37%
Cue Health Inc.	Closed 641,483	$4,138,000
Compass Therapeutics, Inc.	41.30% 1,554,250	$4,119,000	10.38%
Gemini Therapeutics, Inc.	No change 2,435,125	$4,115,000	10.37%
Kinnate Biopharma Inc.	No change 291,667	$3,678,000	9.27%
Cullinan Oncology, LLC	Closed 330,836	$3,464,000
Adicet Bio, Inc.	No change 170,000	$2,482,000	6.26%
Quantum-si Incorporated	60.35% 633,626	$1,470,000	3.70%
Hims & Hers Health, Inc.	Opened 306,431	$1,388,000	3.50%
Enanta Pharmaceuticals Inc	No change 22,750	$1,075,000	2.71%
No transactions found
Showing first 500 out of 11 holdings